Precision For Medicine’s Post

Developing radiopharmaceutical therapies is a challenging process that requires insights from experts in the field. Learn what industry leaders are saying about the development of these complex therapies by exploring Invicro’s latest webinars, case studies, expert interviews and more: https://hubs.ly/Q02c83_g0 #radiopharmaceuticals #theranostics #oncology #radioligandtherapy #imagingCRO

Developing radiopharmaceutical therapies is a challenging process that requires insights from experts in the field. Learn what industry leaders are saying about the development of these complex therapies by exploring Invicro’s latest webinars, case studies, expert interviews and more: https://bit.ly/3Oc1xkO #radiopharmaceuticals #theranostics #oncology #radioligandtherapy #imagingCRO

The #oncology #radiopharmaceutical market is advancing rapidly, with several key players vying for market share. IQVIA's experience and expertise reshape trial pipeline to overcome complexities and executive development process in phase I - IV. Read the fact sheet to learn more: https://bit.ly/4eFQJrq #Radiotherapy #Radiooncology

It’s World Theranostics Day, a time to commemorate the first therapeutic administration of radioiodine to a patient. Dr. Saul Hertz’s 1941 trial helped kickstart the molecular therapy field, which would expand to help patients with a range of diseases. On this day, we celebrate how far the #radiopharmaceutical industry has come and the value of innovative diagnostic and therapeutic solutions.     #WorldTheranosticsDay #prostatecancer #CVD #AlzheimersDisease #oncology

Happy #WorldTheranosticsDay! Theranostics are an important part of what we do at #Lantheus as we #FindFightFollow disease to deliver better patient outcomes. Learn more about Lantheus and #radiopharmaceuticals: https://www.lantheus.com/   #TeamLantheus  

Another attractive molecule to watch at AACR 2024 (April 5-10, San Diego) is EpimAb Biotherapeutics, Inc.’s EMB-07. This ROR1/CD3 bispecific is currently undergoing phase 1 clinical trial and will be featured in the Late-Breaking Research Poster Presentation. EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform led them a deal with Almirall for up to $210M last year. While ROR1 has been a prominent target in recent years, interest waned following the clinical trial failure of Onceternal's zilovertamab. Several ROR1 targeting ADCs and CAR-T therapies are still in development. EpimAb's EMB-07 stands out as one of the two ROR1 targeting T cell engagers in clinical trials. The other, NovalGen's NVG-111, is also in phase 1, with early data suggesting promising efficacy. Anticipation is high for the results of EMB-07, especially given its dual targeting of both liquid and solid tumors. Check link for more detail: https://www.aacr.org Additionally, the 2024 Annual Conference of our society, featuring numerous novel modalities of biologics, will convene in Cambridge, MA, USA on Saturday, May 11, 2024. Registration for the conference is now open via the following link. https://lnkd.in/ecmFPA4v #antibodydiscovery #antibodydrugconjugates#oncology #annualmeeting #annualconference #carttherapy

Need continuing education credit? Enroll in on demand programs like Oncology Biosimilars to earn credit at no additional cost. In this session, gain an overview of the new and emerging oncology biosimilar products, with a focus on utilization trends, substitution considerations, and the managed care and patient advocacy perspectives during this on demand session. https://bit.ly/3NO7y7Z #AMCPLearn #managedcarepharmacy #pharmacy #oncology #biosimilars #continuingeducation

Next kid on the block for #HLA peptide-directed #immunotherapy? Adaptimmune submitted a Biologics License Application (BLA) for their MAGEA4-directed #Tcell #therapy against #SynovialSarcoma. If approved, this would be the first #TCR T cell therapy receiving marketing approval and the second one for HLA peptide targeted therapies after #immunocore's tebentafusb targeting a gp100 epitope on #melanoma #cancer cells. #precisionmedicine #immunopeptidomics

Ratio’s CDO Jacob Hesterman, Ph.D., recently co-authored a paper in the Journal of Clinical Oncology titled, “How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design.”      The article addresses several issues regarding #radiopharmaceutical therapy (RPT) trials in oncology, including the designation of absorbed dose (AD) constraints by the FDA and the dearth of reporting on patient tissue ADs and toxicities.     At Ratio, our commitment to radiopharmaceutical therapies extends beyond the development of our own technology platforms. We’re proud to contribute to improving industry-wide practices for radiopharmaceutical clinical trials. Faster, more efficient trials mean these potentially life-changing treatment reach patients in need sooner.     Read the full article: https://lnkd.in/enH8Rdk6     #radiopharmaceuticals #radiotherapeutics #oncology 

Paper out from Arvinas on pre-clinical characterization of Vepdegestrant (ARV-471). Vepdegestrant was granted Fast Track status by the FDA earlier this year, and is currently being assessed in Phase 3 as a monotherapy and combination therapy with Palbociclib (CDK4/6 inhibitor, Pfizer) in the VERITAC-2 and -3 trials, respectively. The pre-clinical data looks highly promising, with tumour shrinkage in in vivo models when combined with Palbociclib. The paper also contains very thorough mechanistic analysis, demonstrating on-mechanism action and high specificity across the proteome. Paper here: https://lnkd.in/erJEptDC #PROTAC #TPD #Oncology